Back to results

East Tennessee State University

Role of Type 2 Cannabinoid Receptor (CB2) in Atherosclerosis.

Abstract

dc:description.abstract

<p>Atherosclerosis is a macrophage-dominated nonresolving inflammatory disease of the arterial wall. Macrophage processes, including apoptosis, influence lesion development in atherosclerosis. Cannabinoids, compounds structurally related to &#916;<sup>9</sup>-tetrahydrocannabinol (THC), the active ingredient in marijuana, exert their effects through cannabinoid receptors, CB1 and CB2. Cannabinoid treatment, THC or Win55,212-2, reduces atherosclerosis in ApoE-null mice by a mechanism thought to involve CB2. However, the exact role of CB2 in atherosclerosis remains unclear. We found that CB2-null macrophages are resistant to oxysterol/oxLDL-induced apoptosis leading us to hypothesize that CB2 may modulate macrophage apoptosis in atherosclerosis. To determine the functions of CB2 in atherosclerosis, we fed low density lipoprotein receptor-null (Ldlr-/-) and Ldlr-/- mice genetically deficient in CB2, an atherogenic diet for 8 and 12 weeks. CB2 deficiency did not significantly affect aortic root lesion area after 8 or 12 weeks; however, after 12 weeks, CB2-deficient lesions displayed increased lesional macrophage and smooth muscle cell (SMC) content and a ~2-fold reduction in lesional apoptosis. CB2-deficienct lesions also displayed reduced collagen content and elevated elastin fiber fragmentation that was associated with elevated levels of the extracellular matrix degrading enzyme, matrix metalloproteinase 9 (MMP9). These results demonstrate that although CB2 signaling does not affect atherosclerotic lesion size it does modulate lesional apoptosis, cellularity and ECM composition. Ldlr-/- and CB2-deficient Ldlr-/- mice were also subjected to daily treatments with Win55,212-2, a synthetic cannabinoid, over the last 2 weeks of an 8 week atherogenic diet to identify CB2-dependent and CB2-independent effects of cannabinoid receptor stimulation on atherosclerosis. Win55,212-2 did not affect hypercholesterolemia, aortic root lesion area, lesional macrophage infiltration, or ECM composition in either genotype but did significantly reduce total plasma triglyceride levels and lesional SMC content, independent of CB2. Surprisingly, lesional apoptosis was dose-dependently repressed by Win55,212-2 in Ldlr-/- mice by a CB2-dependent mechanism. All together, these results support the suggestion that CB2 may be a target for novel therapies aimed at modulating lesional apoptosis and cellularity to increase lesion stability and reduce the vulnerability to rupture.</p>

Degree

thesis:*
Name thesis:degree_name
PhD (Doctor of Philosophy)
Level thesis:degree_level
Dissertation - restricted
Discipline thesis:degree_discipline
Biomedical Sciences
Year dc:date.issued
2011

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Netherland, Courtney Denise

Subjects

dc:subject × 12

Rights

dc:rights
Statement dc:rights
  • Copyright by the authors.

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dc.etsu.edu/etd/1392
OAI identifier oai:identifier
oai:dc.etsu.edu:etd-2583

Chain of custody

source
Harvested from
East Tennessee State University
Base URL
dc.etsu.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Netherland, Courtney Denise. Role of Type 2 Cannabinoid Receptor (CB2) in Atherosclerosis.. Dissertation - restricted thesis, 2011. https://dc.etsu.edu/etd/1392